2022 Archived Content


Spatial Biology & Single-Cell Analysis

Adding a New Dimension to Multi-Omic Analysis

June 21 - 22, 2022 ALL TIMES EDT

Emerging technologies in spatial biology and single-cell analysis promise to enable better understanding of biological pathways, discovery of new biomarkers and drug targets, and more insightful translational research. Cambridge Healthtech Institute’s Inaugural Spatial Biology & Single-Cell Analysis meeting will explore the latest technologies and research in using spatial multi-omics tools to uncover molecular insights in oncology, neurology, immunology and more.

Tuesday, June 21

ROOM LOCATION Essex North West and North Center


1:30 pm

Chairperson's Remarks

Carsten Krieg, PhD, Assistant Professor, Microbiology & Immunology, Medical University of South Carolina
1:35 pm

Combination of Multi-Omics Multi-Platform Approaches to Gain Insights in Mechanisms of Pathobiology and Biomarker Discovery

Carsten Krieg, PhD, Assistant Professor, Microbiology & Immunology, Medical University of South Carolina

The Krieg lab combines high-dimensional single-cell techniques with bioinformatics analysis to define new cellular biomarkers. Using our workflow, we recently described cellular biomarker signatures to predict the response of patients with melanoma to immunotherapy and patients with therapy-resistant lung cancer to novel combination immunotherapy. In addition, the Krieg lab recently expanded its effort into using multi-platform technologies, such as MALDI-IMS and imaging mass cytometry, to identify and characterize single-cells in tissues.

2:05 pm

Single-Cell Analysis of Tumor and Immune Cell Interactions

Kai Tan, PhD, Professor, Pediatrics, Cell & Development Biology; Genetics Director, Center for Single Cell Biology, Children’s Hospital of Philadelphia Perelman School of Medicine, University of Pennsylvania

Single-cell omics and imaging technologies hold great promise for understanding the complex interactions between tumor and immune cells in the tumor microenvironment. I will present how these technologies can be applied to clinical samples to untangle tumor-immune cell interactions in both leukemia and solid tumors.

2:35 pm

Exploring Functional Protein Covariation across Single Cells

Nikolai Slavov, PhD, Associate Professor, Bioengineering, Northeastern University

Biological functions arise from protein interactions, which are reflected in the natural variation of proteome configurations across individual cells. Emerging single-cell proteomics methods may decode this variation and empower inference of biological mechanisms with minimal assumptions. I will describe both established and emerging single-cell mass-spectrometry methods, and how these methods have allowed us to interpret protein covariation in different biological systems, including primary macrophages and melanoma cells.

3:05 pm Refreshment Break with Exhibit Viewing (Foyer)


3:45 pm

Chairperson's Remarks

Michael Chisamore, PhD, Executive Director, Distinguished Scientist, Oncology Early Development – External Collaborations, Merck & Co., Inc.
3:50 pm

Clinical Lessons on the Importance of Independent Action vs Synergy for Rational Immuno-Oncology Drug Combinations

Michael Chisamore, PhD, Executive Director, Distinguished Scientist, Oncology Early Development – External Collaborations, Merck & Co., Inc.

Historically, cancer drugs are combined orthogonally to overcome resistance. “Independent Action” mathematically tests this approach. In the immuno-oncology (IO) era, efforts to rationally design combinations have led to a surge of trials proposing “synergy.” The failure of scientists to understand pharmacologic synergy may be contributing to increasing futility in moving cancer drugs from Phase 1 to registration. Clinical “synergy” is very rare in drug development, especially in IO combinations.       

4:20 pm

Precision Immunotherapy: What the Genomic Revolution Has Taught Us

Razelle Kurzrock, MD, Professor, Medicine, Associate Director, Clinical Research, Linda T. and John A. Mellowes Endowed Chair of Precision Oncology, Medical College of Wisconsin; CMO, Worldwide Innovative Network (WIN) for Personalized Cancer Therapy

The genomic revolution has demonstrated that targeted drugs, in order to be useful, must be given to patients whose tumors bear the cognate target. For instance, EGFR kinase inhibitors are active against cancers with EGFR kinase mutations, but inactive against cancers without the targeted alteration. Similarly, optimizing immunotherapy will require a precision approach, i.e., identification of malignancies that harbor an immune target modifiable by the specific immunotherapy given.

4:50 pm Close of Day

Wednesday, June 22

7:45 am Morning Coffee (Foyer)

ROOM LOCATION: Essex North West and North Center


8:30 am

Chairperson's Remarks

Fei Chen, PhD, Assistant Professor, Stem Cell & Regenerative Biology, Broad Institute
8:35 am

High-Speed 3D Spatial-Omics

Douglas Shepherd, PhD, Assistant Professor, Biological Physics, Arizona State University

In this talk, we present a rapid 3D molecular imaging and computational suite for highly multiplexed single-molecule RNA-FISH-based spatial transcriptomic approaches. Building on our recent work in high-resolution oblique plane microscopy and model-driven data analysis, this approach provides 3D localization in large samples at speeds equal to or greater than existing microscopy approaches. We provide example results for highly multiplexed RNA-FISH from cells to human tissue slices.

9:05 am

A Toolkit for Multimodal Analysis of Neurodegenerative Disease

Silas Maniatis, PhD, Associate Director, Technology Innovation, New York Genome Center

Given the functional importance of the physical arrangement of diverse cell types and cell states in the CNS, single-cell and spatially resolved –omics methods could provide fundamental insights into the molecular and cellular pathologies in neurodegenerative diseases. We have assembled an accessible toolkit of instrumentation, molecular profiling, and computational technologies for integrative multimodal atlasing of CNS tissues at scale. Using this toolkit, we are generating datasets enabling analysis of the links between genotype, gene regulation, pathology, and clinical presentation.

9:35 am Coffee Break with Exhibit Viewing (Foyer)
10:20 am

Cross-Tissue Organization of the Fibroblast Lineage in Health and Disease

Rachana N. Pradhan, PhD, Postdoctoral Fellow, Oncology Bioinformatics, Genentech

Fibroblasts are non-hematopoietic structural cells that regulate tissue architecture, support homeostasis of tissue-resident cells, and play pivotal roles in biological processes such as fibrosis, cancer, autoimmunity, and wound-healing. We apply multi-modal single cell and spatial methods to identify and characterize universal fibroblasts that serve as a reservoir and yield both specialized fibroblasts across a broad range of steady-state tissues and activated fibroblasts across disease. Our integrative analyses of fibroblasts represent an effort into implementing sophisticated single-cell methods towards the discovery of novel fundamental biology which will yield clinical dividends.

10:50 am

Tissue Genomics: Genomic Measurements in Context

Fei Chen, PhD, Assistant Professor, Stem Cell & Regenerative Biology, Broad Institute

Tissue functions are highly cell non-autonomous. While single-cell analysis has begun to elucidate the cellular components that participate in tissue function and dysfunction; interactions – and their spatial variation across tissue structures – remain challenging to explore. Here, we’ll describe advances in situ and single cell transcriptomic sequencing tools which aim to capture both the spatial context of cells as well as their dynamics within tissues. We will describe efforts to apply these tools to measure, model and manipulate the rules of tissue organization in diverse contexts. More broadly, we’ll discuss the promise and challenges of spatial transcriptomics for tissue genomics.

11:20 am

Multi-Layered Cell and Tissue Interrogation Using Bulk, Single-Cell, and Spatial Transcriptomics

Ioannis Vlachos, PhD, Director, Spatial Technologies, Beth Israel Deaconess Medical Center; Assistant Professor, Pathology, Harvard Medical School; Associate Member, Broad Institute of MIT & Harvard
11:50 am Enjoy Lunch on Your Own

ROOM CHANGE: Essex Center


1:25 pm

Chairperson's Remarks

Akil Merchant, MD, PhD, Associate Professor, Medicine & Director, Imaging Mass Cytometry Core, Cedars-Sinai Medical Center
1:30 pm

Spatial Genomics Reveals Complex Tumor Architecture and Signaling Mechanisms

Eugene Drokhlyansky, PhD, Senior Principal Scientist, Bristol Myers Squibb
Anna Lyubetskaya, PhD, Principal Scientist, Bristol Myers Squibb

Tumor heterogeneity is a major challenge for oncology drug discovery and development. Understanding of the spatial tumor landscape is key to identifying new targets and impactful model systems. We will discuss the utility of spatial transcriptomics (ST) for Oncology Discovery, including digital pathology augmentation, tumor depth correlates, relative cell type attribution and target identification in mouse tumor models and clinical tumor samples.

2:00 pm

Spatially-Resolved Single-Cell Analysis of Lymphoma

Akil Merchant, MD, PhD, Associate Professor, Medicine & Director, Imaging Mass Cytometry Core, Cedars-Sinai Medical Center

Multiplexed immune cell profiling of the tumor microenvironment (TME) has improved our understanding of cancer immunology. We have used imaging mass cytometry (IMC) to characterize the tumor and immune cell architecture of aggressive lymphoma. We integrate tumor mutational profiling, clinical outcomes, and multiplexed immuno-phenotyping of the TME into a spatial analysis of lymphoma at the single cell level and identify candidate biomarkers for treatment response.

2:30 pm

Single-Cell Spatial Omics Journey to Signaling and Metabolism in Situ

Ahmet Coskun, PhD, Assistant Professor, Biomedical Engineering, Georgia Institute of Technology

Cellular “maps” shed light on the spatial regulation mechanisms of many disorders. The next challenge in spatial biology is to link the cellular function to the cell phenotypes in their environments. Image-based multiparameter molecular profiling has the potential to decode high-dimensional dynamics of signaling and metabolism at the subcellular and molecular level in complex tissues and organs. In this talk, I will introduce multiplex imaging modalities (genomics, proteomics, and metabolomics) to decipher the spatial and temporal decision-making of single-cells at macromolecular resolution in engineered organoids and human tissues for systems immuno-engineering, subcellular precision oncology, and personalized regenerative medicine applications.

3:00 pm Close of Conference

Health and Safety

View Media Partners